Practice

Radiographic Progression Comparable in Patients Receiving Etanercept, Biosimilar

October 5th 2017

By Kelly Davio

A phase 3 study comparing Samsung Bioepis’ etanercept biosimilar, SB4, to its reference found that SB4 had comparable efficacy—including radiographic progression—to week 52 of treatment in patients with rheumatoid arthritis.

PBM: Specialty Medications Drive Increased US Prescription Drug Spending

October 4th 2017

By Jackie Syrop

The number of people who had annual prescription medication costs of $50,000 or more in 2016 was 35% higher than it was in 2014, according to pharmacy benefit manager Express Scripts.

Biosimilar Infliximab Effective Against Mycobacterial IRIS in Patients With HIV

October 3rd 2017

By Kelly Davio

While tumor necrosis factor (TNF) deficiency is associated with a higher incidence of tuberculosis, excessive production of TNF is associated with an exaggerated inflammatory response that can result in mycobacterial immune reconstitution inflammatory syndrome (IRIS).

Biosimilar as Effective as Originator G-CSFs in Mobilizing Hematopoietic Stem Cells

September 29th 2017

By Jackie Syrop

The standard way to conduct mobilization in hematopoietic stem cell donors relies on using 2 original granulocyte-colony stimulating factors (G-CSFs), filgrastim (Neupogen) and lenograstim (Granocyte).

Canadian Study Finds High Adherence to Anti-TNF Agents in Inflammatory Diseases

September 26th 2017

By Jackie Syrop

A large Canadian study of patients with inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, reports that a high overall rate of adherence to subcutaneous anti-TNFs.

Bevacizumab-Containing Regimens Improve Survival in NSCLC

September 22nd 2017

By Jackie Syrop

In real-world community oncology settings, bevacizumab-containing regimens were associated with longer progression-free survival and overall survival compared with non-bevacizumab regimens.

PBMs: The Biosimilar Blockade

September 20th 2017

In recent years, a wrench has been thrown into the patient care equation.

Global Experts Provide Consensus-Based Recommendations for Rheumatology Biosimilars

September 18th 2017

By Kelly Davio

In an effort to provide a guide for clinicians and a framework for future educational efforts, an international panel of healthcare stakeholders convened to arrive at consensus recommendations for the use of biosimilars to treat rheumatological diseases.

FDA Approves Mvasi, First Bevacizumab Biosimilar

September 14th 2017

By The Center for Biosimilars Staff

The FDA has approved Mvasi, the first biosimilar bevacizumab (Avastin).

Biosimilars Can Generate Savings, Expand Access

September 14th 2017

By Jackie Syrop

According to a new study, potential savings realized from transitioning to treatment with biosimilar filgrastim-sndz from reference filgrastim are not only significant, but these savings can also be applied to expand access to novel immunotherapies or supportive care.